Abstract
Background: Patients with multiple sclerosis who have poor adherence to treatment have a higher risk of relapse than adherent patients. This study assessed adherence to, and effectiveness and convenience of, treatment with subcutaneous (sc) interferon (IFN) beta-1a (Rebif, Merck Serono SA) 44 or 22 mu g three times weekly in patients with relapsing multiple sclerosis (RMS) using the RebiSmart (R) electronic, multidose, autoinjector for 1 year. Study design: European, multicentre, observational study among neurologists: inclusion criteria included RMS, Expanded Disability Status Scale score
Original language | English |
---|---|
Pages (from-to) | 1239-1250 |
Journal | Expert Opinion on Drug Delivery |
Volume | 12 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2015 |
Keywords
- adherence
- autoinjector
- interferon beta
- multiple sclerosis